Investors who lost money on Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP (“Glancy”) today announced a securities fraud investigation on behalf of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) investors into whether the Company may have violated the federal securities laws. The investigation follows the November 3, 2026 disclosure regarding Madrigal Pharmaceuticals, Inc.
Investors who lost money on Madrigal Pharmaceuticals, Inc. securities can submit their Madrigal Pharmaceuticals, Inc. loss information to learn about potentially pursuing claims to recover their losses.
Key facts in the Madrigal Pharmaceuticals, Inc. investigation
- Disclosure date: November 3, 2026
- Stock price decline: $34.84 per share, or 8.1%
- Closing price after the decline: $396.32 on November 3, 2026
What happened?
On November 3, 2026, Madrigal disclosed in its quarterly report on Form 10-Q that, on October 9, 2026, the Company’s former Senior Vice President, Head of Clinical Development Dr. Michael Charlton filed a Whistleblower complaint against the Company. The complaint states that, “Over the course of roughly eight months, Dr. Charlton repeatedly reported to Madrigal’s most senior executives, including directly to Chief Executive Officer Bill Sibold, and Chief Medical Officer David Soergel, that Madrigal was suppressing adverse liver-injury data, presenting efficacy results that could not be reconciled with their own source data, and allowing an unblinded Board member, former Chief Medical Officer and major shareholder to control the adjudication of clinical outcomes.”
On this news, Madrigal shares fell $34.84 or 8.1%, to close at $396.32 on November 3, 2026, thereby injuring investors.
“The price of Madrigal Pharmaceuticals, Inc. shares fell 8.1% following the November 3, 2026 disclosure that Madrigal disclosed in its Form 10-Q that former Senior Vice President Dr. Michael Charlton had filed a whistleblower complaint on October 9, 2026 alleging the Company suppressed adverse liver-injury data and presented efficacy results that could not be reconciled with source data. Investors who suffered losses deserve to know whether they were given complete and accurate information prior to the disclosure, and our investigation seeks to answer that question,” said Charles H. Linehan, Partner at Glancy Prongay Wolke & Rotter LLP.
What’s the next step?
Glancy is investigating potential claims on behalf of Madrigal Pharmaceuticals, Inc. investors. Investors who lost money can contact Glancy about the Madrigal Pharmaceuticals, Inc. investigation, email shareholders@glancylaw.com, or call 310-201-9150 (toll-free: 888-773-9224).
Frequently Asked Questions
Who is eligible? Investors who bought Madrigal Pharmaceuticals, Inc. securities and lost money may have claims, and can contact Glancy to learn whether they are affected by the Madrigal Pharmaceuticals, Inc. investigation.
What is a securities fraud investigation? In the Madrigal Pharmaceuticals, Inc. investigation, Glancy is reviewing whether the Company or its executives may have made false or misleading statements to investors in violation of the federal securities laws.
Has a lawsuit been filed? This release announces Glancy’s investigation, not a lawsuit. If a securities class action is later filed against Madrigal Pharmaceuticals, Inc., investors may have the opportunity to seek appointment as lead plaintiff.
Does it cost anything to contact Glancy or participate in this investigation? Glancy represents Madrigal Pharmaceuticals, Inc. investors on a contingency fee basis, so investors pay no attorneys’ fees out of pocket. Any attorneys’ fees and litigation expenses are paid only from a recovery, if one is obtained, and are subject to court approval.
Why work with Glancy on the Madrigal Pharmaceuticals, Inc. investigation? Glancy Prongay Wolke & Rotter LLP is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Contact Glancy about the Madrigal Pharmaceuticals, Inc. investigation. Prior results do not guarantee a similar outcome.
Whistleblower notice
Persons with non-public information about Madrigal Pharmaceuticals, Inc. should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information that leads to a successful SEC enforcement action may receive awards of 10 to 30 percent of the sanctions collected, when those sanctions exceed $1 million. For more information, contact Charles H. Linehan at 310-201-9150 or 888-773-9224, or email shareholders@glancylaw.com.
About Glancy Prongay Wolke & Rotter LLP
Glancy was named one of Law360’s Securities Groups of the Year and ranked second in total investor recoveries by ISS Securities Class Action Services in 2025.
Glancy’s successes have been widely covered by leading news and industry publications, including The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money.
Prior results do not guarantee a similar outcome.
Related links
- Madrigal Pharmaceuticals, Inc. investigation page, Glancy Prongay Wolke & Rotter LLP
- Madrigal Form 10-Q
- Madrigal Pharmaceuticals, Inc. SEC filings index, EDGAR
- SEC Whistleblower Program
- Glancy Prongay Wolke & Rotter LLP
Follow Glancy on LinkedIn, X, or Facebook.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261106981831/en/
Media gallery
